BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Yes Securities Report
Alembic Pharmaceuticals Ltd. clocked 11% growth in Q4, on the back of strong growth in India business which continued its outperformance versus Indian pharma market.
U.S. business delivered a surprisingly good quarter driven by inventory stocking, one-time sales of few products and market share ramp up in existing business.
Alembic Pharma also acquired remaining 40% of Aleor Dermaceuticals Ltd. business making it a wholly owned subsidiary; company wrote off Rs 1.88 billion in Aleor reearcj and development with another Rs 1.5 billion to be written off in FY23.
Alembic Pharma guided to $55 million as the base U.S. business (with Q4 at $74 million) even as Q1 is likely to exceed the base number as one-off opportunities still persist.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR